Nevermind Monoclonal TNF-alpha blockers use Zyban ! (aka Bupropion)

Re: Nevermind TNF-alpha blockers use Zyban !

Bupropion and chronic aphthous ulceration

RE Kast, EL Altschuler - Archives of Dermatology, 2005 - Am Med Assoc

We report a case of durable remission of chronic, recurrent oral aphthous
ulceations (RAUs) of the mouth during treat- ment with the antidepressant
bupropion hydrochlo- ride. In 1984, Rosenthal 1 reported that RAUs resolved ...

Re: Nevermind TNF-alpha blockers use Zyban !

Interesting List of good Bupropion and TNF-alpha pearls !


http://scholar.google.ca/scholar?hl=en&lr=&q=bupropion+Altschuler&btnG=Search



http://www.expert-reviews.com/doi/abs/10.1586/14737175.6.9.1249



Bupropion: pharmacology and therapeutic applications
Kevin F Foley†, Kevin P DeSanty and Richard E Kast

A total of 17 years after its introduction, bupropion remains a safe and effective antidepressant, suitable for first-line use. Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybupropion, through hepatic cytochrome P450-2B6 (CYP2B6) and has inhibitory effects on cytochrome P450-2D6 (CYP2D6), thus raising concern for clinically-relevant drug interactions. Common side effects are nervousness and insomnia. Nausea appears slightly less common than with the SSRI drugs and sexual dysfunction is probably the least of any antidepressant. Bupropion is relatively safe in overdose with seizures being the predominant concern. The mechanism of action of bupropion is still uncertain but may be related to inhibition of presynaptic dopamine and norepinephrine reuptake transporters. The activity of vesicular monoamine transporter-2, the transporter pumping dopamine, norepinephrine and serotonin from the cytosol into presynaptic vesicles, is increased by bupropion and may be a component of its mechanism of action. Bupropion is approved for use in major depression and seasonal affective disorder and has demonstrated comparable efficacy to other antidepressants in clinical trials. Bupropion is also useful in augmenting a partial response to selective serotonin reuptake inhibitor antidepressants, although bupropion should not be combined with monoamine oxidase inhibitors. It may be less likely to provoke mania than antidepressants with prominent serotonergic effects. Bupropion is effective in helping people quit tobacco smoking. Anecdotal reports indicate bupropion may lower inflammatory mediators such as tumor necrosis factor-?, may lower fatigue in cancer and may help reduce concentration problems.

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

Title:
Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion.
Author(s):
Kast RE; Altschuler EL
Source:
Gut [Gut] 2004 Jul; Vol. 53 (7), pp. 1056.
Publication Type:
Comment; Letter
Journal Information:
Country of Publication: England NLM ID: 2985108R Publication Model: Print Cited Medium: Print ISSN: 0017-5749 (Print) NLM ISO Abbreviation: Gut Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms:
Bupropion/*therapeutic use
Crohn Disease/*complications
Osteoporosis/*etiology
Antidepressive Agents, Second-Generation/therapeutic use; Bone Density/drug effects; Humans; Tumor Necrosis Factor-alpha/physiology
Comments:
Comment on: Gut. 2004 Feb;53(2):251-5. (PMID: 14724159)
CAS Registry Number:
0 (Antidepressive Agents, Second-Generation)
0 (Tumor Necrosis Factor-alpha)
34841-39-9 (Bupropion)
Entry Date(s):
Date Created: 20040614 Date Completed: 20040716 Latest Revision: 20081120
Update Code:
20081217
PubMed Central ID:
PMC1774110
PMID:
15194665
Persistent link to this record (Permalink):
http://wf2dnvr10.webfeat.org:80/orH...;db=cmedm&AN=15194665&site=ehost-live
Cut and Paste:
<A href="http://wf2dnvr10.webfeat.org:80/orH...edm&amp;AN=15194665&amp;site=ehost-live">Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion.</A>
Database:
MEDLINE

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

Title:
Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels.

Cut and Paste:

Code:

<A href="http://wf2dnvr10.webfeat.org:80/orHEM1157/url=http://search.ebscohost.com/login.aspx?direct=true&amp;db=cmedm&amp;AN=14706417&amp;site=ehost-live">Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels.</A>

Database: MEDLINE

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

Title:
Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha.
Author(s):
Kast RE; Altschuler EL
Author's Address:
University of Vermont,Burlington,VT 05401,USA. rekast@email.com
Source:
Archivum Immunologiae Et Therapiae Experimentalis [Arch Immunol Ther Exp (Warsz)] 2005 Mar-Apr; Vol. 53 (2), pp. 143-7.
Publication Type:
Journal Article; Review
Journal Information:
Country of Publication: Poland NLM ID: 0114365 Publication Model: Print Cited Medium: Print ISSN: 0004-069X (Print) NLM ISO Abbreviation: Arch. Immunol. Ther. Exp. (Warsz.) Subsets: MEDLINE
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell/*immunology
Leukemia, Lymphocytic, Chronic, B-Cell/*therapy
Tumor Necrosis Factor-alpha/*physiology
Antineoplastic Agents/pharmacology; Apoptosis; B-Lymphocytes/immunology; Bupropion/pharmacology; Crohn Disease/immunology; Crohn Disease/pathology; Crohn Disease/therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/pathology; T-Lymphocytes/immunology; Tumor Necrosis Factor-alpha/antagonists &amp; inhibitors
Abstract:
Crohn's disease and B cell chronic lymphocytic leukemia (CLL) share a common link in their pathologic mechanisms. Lymphocytes in both diseases fail to undergo apoptosis and die properly. That failure is partly due to increased signaling by tumor necrosis factor (TNF)-alpha, and their respective pathologies directly follow from this apoptosis failure. Bupropion is a commonly used generic antidepressant in clinical use for over a decade, and early evidence indicates it lowers TNF levels. This paper suggests the use of bupropion in CLL to lower TNF levels, which may thereby slow CLL disease course.
Number of References:
34
CAS Registry Number:
0 (Antineoplastic Agents)
0 (Tumor Necrosis Factor-alpha)
34841-39-9 (Bupropion)
Entry Date(s):
Date Created: 20050601 Date Completed: 20050824 Latest Revision: 20071115
Update Code:
20081217
PMID:
15928583
Persistent link to this record (Permalink):
http://wf2dnvr10.webfeat.org:80/orH...;db=cmedm&amp;AN=15928583&amp;site=ehost-live
Cut and Paste:
<A href="http://wf2dnvr10.webfeat.org:80/orH...=15928583&amp;site=ehost-live">Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha.</A>
Database:
MEDLINE

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder
http://www.springerlink.com/content/2b7dtpj253blu9cu/

Cengiz Tuglu1 Contact Information, S. Hakan Kara1, Okan Caliyurt1, Erdal Vardar1 and Ercan Abay1
(1) Department of Psychiatry, Trakya University, School of Medicine, 22030 Edirne, Turkey

Contact Information Cengiz Tuglu
Email: ctuglu@hotmail.com
Phone: +90-284-2358942
Fax: +90-284-2353881

Received: 18 March 2003 Accepted: 13 June 2003 Published online: 30 August 2003
Abstract
Rationale Over the last 15 years, an increasing body of evidence has suggested a causal relationship between depression and the immunological activation and hypersecretion of pro-inflammatory cytokines, such as interleukin-1, interleukin-6 and tumor necrosis factor-alpha (TNF-agr). However, little is known about the probable relationship of serum TNF-agr with major depressive disorder (MDD).
Objective To assess whether serum TNF-agr levels could be associated with the clinical course of MDD.
Subjects and methods TNF-agr and C-reactive protein (CRP) serum concentrations, erythrocyte sedimentation rate, and leukocyte count were measured in 26 MDD patients and in 17 controls. The measurements were repeated following 6 weeks of antidepressant treatment with selective serotonin re-uptake inhibitors. Psychopathological improvement and the severity of depression were evaluated with the Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI).
Results On admission, serum TNF-agr and leukocyte count were significantly higher in MDD patients compared to controls (P<0.001 and P=0.005, respectively). With the antidepressant treatment, both HAMD and BDI scores decreased significantly (P<0.001 for both). Comparison of pre- and post-treatment measurements revealed that TNF-agr, CRP, and leukocyte count decreased to levels comparable with those of the control subjects (P<0.001, P=0.01, and P=0.01, respectively).
Conclusions The results emphasized that some immunological parameters, such as CRP, leukocyte count and TNF-agr, are significantly involved in the clinical course and treatment response in MDD. TNF-agr in particular could be considered as a potential state marker in MDD.

Keywords Major depression - Tumor necrosis factor - Treatment response - Cytokine - SSRI

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

Restless legs syndrome induced by citalopram: a psychiatric emergency?

Nader P, Coralie L, Baleydier B, Andrei C, Susanne M, Damsa C.

Service d'accueil, d'urgence et de liaison psychiatrique, Universitary Hospital Geneva, 1211 Geneva, Switzerland.

OBJECTIVE: The objective of this case report is to create awareness on restless legs syndrome (RLS) among clinicians working in emergency units.

METHOD: We describe a case reporting important aggravation of RLS associated with citalopram, 60 mg/day, in a 48-year-old woman who was sent to the emergency unit by her general practitioner. Citalopram was replaced by bupropion, 150 mg/day, and sertraline, 50 mg/day.

RESULTS: Three days later, symptoms of RLS started to diminish and, after 3 weeks, clinical symptoms had disappeared entirely. On 6-month follow-up, the patient did not manifest clinically significant RLS. Ignoring RLS could lead to a worsening of symptoms and could increase the risk for iatrogenic conditions. The prevalence of RLS in the general population is 3-9%; nevertheless, this syndrome is frequently underdiagnosed.

CONCLUSION: This case report suggests that RLS could be considered as a possible "dopamine-dependent side effect" of selective serotonin reuptake inhibitors (SSRIs). Bupropion could potentially "correct" dopaminergic dysfunction in RLS, and sertraline appears to be the SSRI that provides the least risk of RLS by blocking dopamine reuptake.

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha.


Author(s): Kast RE; Altschuler EL
Author's Address: University of Vermont,Burlington,VT 05401,USA. rekast@email.com
Source: Archivum Immunologiae Et Therapiae Experimentalis [Arch Immunol Ther Exp (Warsz)] 2005 Mar-Apr; Vol. 53 (2), pp. 143-7.
Publication Type: Journal Article; Review
Journal Information: Country of Publication: Poland NLM ID: 0114365 Publication Model: Print Cited Medium: Print ISSN: 0004-069X (Print) NLM ISO Abbreviation: Arch. Immunol. Ther. Exp. (Warsz.) Subsets: MEDLINE
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell/*immunology
Leukemia, Lymphocytic, Chronic, B-Cell/*therapy
Tumor Necrosis Factor-alpha/*physiology
Antineoplastic Agents/pharmacology; Apoptosis; B-Lymphocytes/immunology; Bupropion/pharmacology; Crohn Disease/immunology; Crohn Disease/pathology; Crohn Disease/therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/pathology; T-Lymphocytes/immunology; Tumor Necrosis Factor-alpha/antagonists &amp; inhibitors


Abstract:
Crohn's disease and B cell chronic lymphocytic leukemia (CLL) share a common link in their pathologic mechanisms. Lymphocytes in both diseases fail to undergo apoptosis and die properly. That failure is partly due to increased signaling by tumor necrosis factor (TNF)-alpha, and their respective pathologies directly follow from this apoptosis failure. Bupropion is a commonly used generic antidepressant in clinical use for over a decade, and early evidence indicates it lowers TNF levels. This paper suggests the use of bupropion in CLL to lower TNF levels, which may thereby slow CLL disease course.


Number of References: 34
CAS Registry Number: 0 (Antineoplastic Agents) 0 (Tumor Necrosis Factor-alpha) 34841-39-9 (Bupropion)
Entry Date(s): Date Created: 20050601 Date Completed: 20050824 Latest Revision: 20071115
Update Code: 20081217 PMID: 15928583
Persistent link to this record (Permalink):
Database: MEDLINE

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

Heh.

http://www.freepatentsonline.com/y2006/0173080.html

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

TNF blockers get new safety warning - lymphoma mentioned now as a specific cause of possible malignancy.

Re: Nevermind monoclonal antibody TNF-alpha blockers use Zyban !

I wonder how they are going to tease out from the increased risk of lymphoma in RA anyway.

Perhaps they should mix in some rituximab with the anti-tnfs

Hey. Page one of TNF alpha Wellbutrin.

Seems like this Buproprion as an anti-inflammatory has taken off.

https://www.cnn.com/2017/12/19/heal...sants-bowel-crohns-disease-partner/index.html